Clinical Trials Sponsored by Cortria Corporation

Total 6611 results

Cortria Corporation

Completed

The Safety of a Hypolipidemic Agent in Healthy Normal Volunteers (Cortria-002)

Healthy
Cortria Corporation

Completed

A Study to Evaluate the Lipid Regulating Effects of TRIA-662

Hyperlipidemia
Cortria Corporation
Montreal Heart Institute

Completed

A Pilot Study to Evaluate the Lipid Effects of TRIA-662

Hypertriglyceridemia | Mixed Hyperlipidemia

Canada
Cortria Corporation
PPD; Pharmena North America

Completed

Comparison of TRIA-662 500 mg and Niaspan 1000 mg in Healthy Male and Female Volunteers Under Fed Conditions

Healthy

Canada
Corteria Pharmaceuticals

Completed

Multiparametric Assessment of Cardiac Congestion in Outpatient Worsening Heart Failure (EVOLUTION)

Heart Failure | Heart Decompensation

Armenia, Bosnia and Herzegovina
GenMont Biotech Incorporation
Biomedical Development Corporation

Completed

the Efficacy and Safety of Probiotics eN-Lac® Capsules of Children With Perennial Allergic Rhinitis (PAR)

Probiotics | Perennial Allergic Rhinitis | Lactobacillus Paracasei GMNL-32 (eN-Lac®)

Taiwan
Corvia Medical

Recruiting

REDUCE LAP-HF III Corvia Protocol 1701 (REDUCELAPHFIII)

Heart Failure

Germany, Switzerland
Corvia Medical

Active, not recruiting

REDUCE LAP-HFREF TRIAL

Heart Failure

Australia, United States, Czechia
Corvia Medical

Active, not recruiting

REDUCE LAP-HF RANDOMIZED TRIAL I

Heart Failure

United States, Netherlands, Australia, Belgium, United Kingdom
Corvia Medical

Withdrawn

Extended IASD Investigation: REDUCE LAP-HF IV

Heart Failure With Preserved Ejection Fraction | Heart Failure With Mid Range Ejection Fraction
Floreo, Inc.
Cortica

Completed

Virtual Reality Intervention for Skill Acquisition Support in Autism Spectrum Disorder (ASD)

Autism Spectrum Disorder

United States
Corvia Medical

Recruiting

RESPONDER-HF Trial

Heart Failure | Heart Failure, Diastolic

United States, Germany, Australia, Netherlands, Belgium, Austria
Corvia Medical

Active, not recruiting

REDUCE LAP-HF TRIAL II

Heart Failure

United States, Austria, Japan, Australia, Netherlands, Canada, France, Denmark, Germany, Spain, Italy, Belgium, Croatia, Poland, United Kingdom
Corvia Medical

Completed

Feasibility Trial of the DC Devices Interatrial Septal Device (IASD) System

Heart Failure

Denmark, Australia, Czechia
Corvia Medical

Completed

REDUCE LAP-HF TRIAL (REDUCE LAP-HF)

Heart Failure

New Zealand, Austria, France, Denmark, Germany, Netherlands, United Kingdom, Australia, Czechia, Belgium, Poland
Stryker Craniomaxillofacial
Fortrea

Enrolling by invitation

Adherus™ Dural Sealant in Spinal Procedures

Spinal Duraplasty

United States
Volta Medical
Fortrea

Recruiting

Clinical and Healthcare Economic OutcoMes From ReAl-worlD Use in Europe of an AI Software During AF Ablation (COMRADE-AI)

Atrial Fibrillation | Arrhythmias, Cardiac | Atrial Arrhythmia

France
NanoPin Technologies, Inc.
Fortrea

Not yet recruiting

Clinical Evaluation of the NanoDetect-TB Mycobacterium Tuberculosis Detection Kit for the Diagnosis of Tuberculosis Disease

Tuberculosis, Pulmonary | Tuberculosis, Extrapulmonary | Tuberculosis Active
GE Healthcare
Fortrea, Inc.

Recruiting

Altropane Dose for Imaging Patients With Suspected Parkinson's Disease

Parkinson Disease | Movement Disorders

United States
Digital Diagnostics, Inc.
Fortrea

Active, not recruiting

Camera Qualification Study

Diabetic Retinopathy

United States
GE Healthcare
PPD; Fortrea

Not yet recruiting

A Phase 1, Dose-Escalation, Positron Emission Tomography Study to Assess the Safety, Pharmacokinetics, Dosimetry and Biodistribution of GEH200521 (18F) Injection Co-Administered With GEH200520 Injection in Healthy Volunteers

Healthy Volunteers

United States
Cortrium
University College Absalon

Completed

Clinical Testing of the Cortrium C3 Device

Cancer

Germany
Contra Costa Health Services

Unknown

Contra Costa Health Services Whole Person Care (CommunityConnect) Program Evaluation (CCHS-WPC)

Social Determinants of Health

United States
Coria Laboratories, Ltd.

Completed

Effect of Tetrix on Alleviation of Burning,Itching Associated With Lesions of Contact Dermatitis

Contact Dermatitis

United States
Coria Laboratories, Ltd.

Completed

Evaluation of Tetrix Cream as a Protective Barrier Against Injurious Materials

Healthy

United States
Coria Laboratories, Ltd.

Completed

Study to Determine if Tetrix Cream is Removed From the Hands by Gentle Washing With Soap and Water

Healthy

United States
Innovent Biologics (Suzhou) Co. Ltd.
Fortrea

Completed

Sintilimab or Placebo With Chemotherapy in Esophageal Squamous Cell Carcinoma ( ORIENT-15 ) (ORIENT-15)

Esophageal Squamous Cell Carcinoma

France, Spain, Belgium, Australia, United States, China, Hungary
Asociación Española contra el Cáncer

Completed

How to Carry on an Effective Community Program of Exercice-oncology.

Cancer Patients in Different Stages

Spain
Centro Universitario contra el Cáncer

Completed

Biweekly Docetaxel in Patients With Metastatic Breast Cancer.

Metastatic Breast Cancer

Mexico
Coria Laboratories, Ltd.

Completed

A Study to Determine the Safety and Efficacy of Atralin (Tretinoin 0.05%) Gel for the Treatment of Rosacea

Rosacea

United States
Coria Laboratories, Ltd.

Completed

Evaluation of Tetrix Cream in the Healing of Injured Skin in Subjects With Contact Dermatitis

Healthy

United States
Coria Laboratories, Ltd.

Completed

Clinical Evaluation of the Photoallergy Potential of Atralin Gel

Healthy

United States
Coria Laboratories, Ltd.

Completed

Study to Determine the Phototoxity of Atralin (Tretinoin) Gel, 0.05%

Healthy

United States
Boston Scientific Corporation
Guidant Corporation

Completed

Septal - Success Rate and Clinical Outcome of Septal Implant of Ventricular Defibrillation Lead

Ventricular Fibrillation | Ventricular Tachycardia

France
Boston Scientific Corporation
Guidant Corporation

Completed

Shockless Implant Evaluation (SIMPLE)

Ventricular Fibrillation | Ventricular Tachycardia

Germany, Spain, Canada, Israel, Netherlands, France, Finland, United Kingdom, Austria, Malaysia, Thailand, Hong Kong, Sweden, Hungary, Australia, Czechia, Norway, Poland
Boston Scientific Corporation
Guidant Corporation

Completed

Feature Assessment Study for Indications Based Programming (FASt-IBP)

Heart Failure | Ventricular Fibrillation | Ventricular Tachycardia | Ventricular Flutter

Germany, Spain, Switzerland, China, Austria, Belgium, France, Greece, Latvia, Netherlands, Slovakia
Boston Scientific Corporation
Guidant Corporation

Completed

Japanese Assessment of Indication Based Programming (JASMINE)

Heart Failure | Arrhythmias, Cardiac

Japan
Boston Scientific Corporation
Guidant Corporation

Completed

Quick ICD Study: Is Extensive Electrophysiological Testing Before, During and After ICD-Implantation Still Necessary ? (Quick ICD)

Cardiac Arrest

Germany
Rgene Corporation
American BriVision Corporation

Not yet recruiting

Evaluate the Safety and Efficacy of BLEX 404 Oral Liquid Combined With Pemetrexed + Cisplatin Therapy

Nonsquamous Nonsmall Cell Neoplasm of Lung

Taiwan
Rgene Corporation
American BriVision Corporation

Not yet recruiting

A Phase II, EvaluateBLEX 404 Combined With Gemcitabine Monotherapy With Pancreatic Cancer

Pancreatic Cancer
Boston Scientific Corporation
Guidant Corporation

Terminated

MODULA Modul 7 VRR

Atrial Fibrillation

Germany
Boston Scientific Corporation
EKOS Corporation

Completed

ULTrasound Accelerated ThrombolysIs of PulMonAry Embolism (ULTIMA)

Submassive Pulmonary Embolism

Germany, Switzerland
Boston Scientific Corporation
EKOS Corporation

Completed

Optimum Duration of Acoustic Pulse Thrombolysis Procedure in Acute Pulmonary Embolism (OPTALYSE PE)

Pulmonary Embolism and Thrombosis

United States, United Kingdom
Boston Scientific Corporation
EKOS Corporation

Completed

Submassive and Massive Pulmonary Embolism Treatment With Ultrasound Accelerated Thrombolysis Therapy (SEATTLE II)

Pulmonary Embolism | Acute Pulmonary Embolism | Pulmonary Thromboembolism | Massive Pulmonary Embolism | Sub-massive Pulmonary Embolism

United States
Boston Scientific Corporation
Guidant Corporation

Completed

MODULA Modul 5 BEAT-HF

Heart Failure

Germany
Boston Scientific Corporation
Guidant Corporation

Terminated

MODULA-Study: Modul 10: Benefit of CRT-Therapy in CRT-Patients With QRS-Complex of 120 - 150 Ms

Heart Failure

Germany
Guidant Corporation
Boston Scientific Corporation

Completed

Cognis and Teligen 100 HE and Reliance Quadripolar Defibrillation Lead (4-Site) Field Following (Cogent-4)

Heart Failure | Ventricular Tachycardia, Ventricular Fibrillation

Israel, Denmark
Boston Scientific Corporation
EKOS Corporation

Withdrawn

Registry Study to Evaluate the Performance and Safety of Roxwood Medical Catheters in Arteries of Participants With a Stenotic Lesion or Chronic Total Occlusion (CTO)

Coronary Artery Disease | Atherosclerosis | Peripheral Artery Disease | Chronic Total Occlusion

United States
Boston Scientific Corporation
EKOS Corporation

Completed

Treatment of Chronic Deep Vein Thrombosis (DVT) and Post-Thrombotic Syndrome (PTS) With the EkoSonic® Endovascular System (ACCESS PTS)

Deep Vein Thrombosis | Post-thrombotic Syndrome

United States
Guidant Corporation
Boston Scientific Corporation

Completed

Comparison of Right Ventricular Septal and Right Ventricular Apical Pacing in Patients Receiving a CRT-D Device (SEPTAL-CRT)

Ventricular Fibrillation | Ventricular Tachycardia | Systolic Heart Failure

France, Spain

Clinical Trials Sponsored by Cortria Corporation

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Ukraine

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations